Lin Shao-Lee
Insider CIK 1725092 · HZNP EVP, Head of R&D and CSO · PRNB Director · CUE Chief Executive Officer, Director · SRZN Director · THRD Director · SLRN Chief Executive Officer, Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| CUE Cue Biopharma, Inc. | S Sale | 2026-10-12 | 2026-10-14 | 1,087 | $28.05 | $30.5K | 694,908 | SEC↗ |
| CUE Cue Biopharma, Inc. | S Sale | 2026-10-12 | 2026-10-14 | 10,000 | $27.50 | $275.0K | 695,995 | SEC↗ |
| CUE Cue Biopharma, Inc. | S Sale | 2026-08-13 | 2026-08-14 | 2,375 | $28.11 | $66.8K | 716,455 | SEC↗ |
| CUE Cue Biopharma, Inc. | S Sale | 2026-08-13 | 2026-08-14 | 10,460 | $29.48 | $308.4K | 705,995 | SEC↗ |
| CUE Cue Biopharma, Inc. | S Sale | 2026-08-13 | 2026-08-14 | 5,423 | $27.19 | $147.5K | 718,830 | SEC↗ |
| CUE Cue Biopharma, Inc. | S Sale | 2026-08-13 | 2026-08-14 | 10,460 | $29.48 | $308.4K | 705,995 | SEC↗ |
| CUE Cue Biopharma, Inc. | S Sale | 2026-08-13 | 2026-08-14 | 2,375 | $28.11 | $66.8K | 716,455 | SEC↗ |
| CUE Cue Biopharma, Inc. | S Sale | 2026-08-13 | 2026-08-14 | 5,423 | $27.19 | $147.5K | 718,830 | SEC↗ |
| CUE Cue Biopharma, Inc. | M Exercise deriv | 2026-08-12 | 2026-08-14 | 109,179 | — | $0 | 218,358 | SEC↗ |
| CUE Cue Biopharma, Inc. | S Sale | 2026-08-12 | 2026-08-14 | 5,775 | $27.75 | $160.3K | 724,253 | SEC↗ |
| CUE Cue Biopharma, Inc. | M Exercise | 2026-08-12 | 2026-08-14 | 109,179 | — | $0 | 764,253 | SEC↗ |
| CUE Cue Biopharma, Inc. | S Sale | 2026-08-12 | 2026-08-14 | 34,225 | $26.99 | $923.7K | 730,028 | SEC↗ |
| CUE Cue Biopharma, Inc. | M Exercise deriv | 2026-08-12 | 2026-08-14 | 109,179 | — | $0 | 218,358 | SEC↗ |
| CUE Cue Biopharma, Inc. | S Sale | 2026-08-12 | 2026-08-14 | 5,775 | $27.75 | $160.3K | 724,253 | SEC↗ |
| CUE Cue Biopharma, Inc. | S Sale | 2026-08-12 | 2026-08-14 | 34,225 | $26.99 | $923.7K | 730,028 | SEC↗ |
| CUE Cue Biopharma, Inc. | M Exercise | 2026-08-12 | 2026-08-14 | 109,179 | — | $0 | 764,253 | SEC↗ |
| CUE Cue Biopharma, Inc. | A Award deriv | 2026-07-09 | 2026-07-10 | 327,537 | — | $0 | 327,537 | SEC↗ |
| CUE Cue Biopharma, Inc. | A Award | 2026-07-09 | 2026-07-10 | 327,537 | — | $0 | 655,074 | SEC↗ |
| CUE Cue Biopharma, Inc. | A Award deriv | 2026-06-01 | 2026-07-30 | 45,453 | — | $0 | 45,453 | SEC↗ |
| CUE Cue Biopharma, Inc. | A Award deriv | 2026-06-01 | 2026-07-30 | 90,906 | $11.00 | $1000.0K | 90,906 | SEC↗ |
| CUE Cue Biopharma, Inc. | P Buy deriv | 2026-06-01 | 2026-06-03 | 90,906 | $11.00 | $1000.0K | 90,906 | SEC↗ |
| CUE Cue Biopharma, Inc. | P Buy deriv | 2026-06-01 | 2026-06-03 | 45,453 | — | $0 | 45,453 | SEC↗ |
| CUE Cue Biopharma, Inc. | A Award deriv | 2026-06-01 | 2026-07-30 | 45,453 | — | — | 45,453 | SEC↗ |
| CUE Cue Biopharma, Inc. | A Award deriv | 2026-06-01 | 2026-07-30 | 90,906 | $11.00 | $1000.0K | 90,906 | SEC↗ |
| CUE Cue Biopharma, Inc. | A Award deriv | 2026-05-03 | 2026-05-07 | 655,074 | — | $0 | 655,074 | SEC↗ |
| CUE Cue Biopharma, Inc. | A Award | 2026-05-03 | 2026-05-07 | 327,537 | — | $0 | 327,537 | SEC↗ |
| SRZN Surrozen, Inc./DE | A Award deriv | 2025-05-14 | 2025-05-15 | 1,333 | — | $0 | 1,333 | SEC↗ |
| SRZN Surrozen, Inc./DE | A Award deriv | 2024-06-05 | 2024-06-06 | 1,333 | — | $0 | 1,333 | SEC↗ |
| SLRN ACELYRIN, Inc. | S Sale | 2024-04-01 | 2024-04-03 | 9,961 | $6.63 | $66.0K | 1,577,374 | SEC↗ |
| SLRN ACELYRIN, Inc. | S Sale | 2024-02-20 | 2024-02-22 | 15,701 | $7.60 | $119.3K | 1,587,335 | SEC↗ |
| SLRN ACELYRIN, Inc. | A Award deriv | 2024-01-09 | 2024-01-11 | 964,829 | — | $0 | 964,829 | SEC↗ |
| SLRN ACELYRIN, Inc. | A Award deriv | 2024-01-09 | 2024-01-11 | 413,498 | — | $0 | 413,498 | SEC↗ |
| SLRN ACELYRIN, Inc. | S Sale | 2024-01-02 | 2024-01-04 | 10,691 | $7.41 | $79.2K | 1,603,036 | SEC↗ |
| SLRN ACELYRIN, Inc. | J Other | 2023-10-04 | 2023-10-06 | 132,236 | — | $0 | 487,205 | SEC↗ |
| SLRN ACELYRIN, Inc. | J Other | 2023-10-04 | 2023-10-06 | 1,161,747 | — | $0 | 0 | SEC↗ |
| SLRN ACELYRIN, Inc. | A Award | 2023-08-16 | 2023-08-18 | 842,400 | — | $0 | 1,612,434 | SEC↗ |
| SRZN Surrozen, Inc./DE | A Award deriv | 2023-05-18 | 2023-05-19 | 20,000 | — | $0 | 20,000 | SEC↗ |
| SLRN ACELYRIN, Inc. | J Other deriv | 2023-05-09 | 2023-05-11 | 774,788 | — | $0 | 0 | SEC↗ |
| SLRN ACELYRIN, Inc. | J Other deriv | 2023-05-09 | 2023-05-11 | 774,788 | — | $0 | 774,788 | SEC↗ |
| SLRN ACELYRIN, Inc. | C Conversion deriv | 2023-05-09 | 2023-05-11 | 183,433 | — | $0 | 0 | SEC↗ |
| SLRN ACELYRIN, Inc. | C Conversion deriv | 2023-05-09 | 2023-05-11 | 978,314 | — | $0 | 0 | SEC↗ |
| SLRN ACELYRIN, Inc. | J Other | 2023-05-09 | 2023-05-11 | 354,969 | — | $0 | 354,969 | SEC↗ |
| SLRN ACELYRIN, Inc. | J Other | 2023-05-09 | 2023-05-11 | 349,898 | — | $0 | 0 | SEC↗ |
| SLRN ACELYRIN, Inc. | J Other | 2023-05-09 | 2023-05-11 | 354,969 | — | $0 | 0 | SEC↗ |
| SLRN ACELYRIN, Inc. | J Other | 2023-05-09 | 2023-05-11 | 5,070 | — | $0 | 0 | SEC↗ |
| SLRN ACELYRIN, Inc. | J Other | 2023-05-09 | 2023-05-11 | 5,070 | — | $0 | 5,070 | SEC↗ |
| SLRN ACELYRIN, Inc. | C Conversion | 2023-05-09 | 2023-05-11 | 1,161,747 | — | $0 | 1,161,747 | SEC↗ |
| SLRN ACELYRIN, Inc. | J Other | 2023-05-09 | 2023-05-11 | 1,107,213 | — | $0 | 0 | SEC↗ |
| SLRN ACELYRIN, Inc. | F Tax w/h | 2023-05-09 | 2023-05-11 | 337,179 | $24.69 | $8.32M | 770,034 | SEC↗ |
| SLRN ACELYRIN, Inc. | J Other | 2023-05-09 | 2023-05-11 | 677,813 | — | $0 | 0 | SEC↗ |
| SLRN ACELYRIN, Inc. | J Other | 2023-05-09 | 2023-05-11 | 677,813 | — | $0 | 677,813 | SEC↗ |
| SLRN ACELYRIN, Inc. | J Other | 2023-05-09 | 2023-05-11 | 354,969 | — | $0 | 0 | SEC↗ |
| SLRN ACELYRIN, Inc. | J Other | 2023-05-09 | 2023-05-11 | 354,969 | — | $0 | 354,969 | SEC↗ |
| SLRN ACELYRIN, Inc. | J Other | 2023-05-09 | 2023-05-11 | 349,898 | — | $0 | 349,898 | SEC↗ |
| SLRN ACELYRIN, Inc. | J Other | 2023-05-09 | 2023-05-11 | 1,107,213 | — | $0 | 1,107,213 | SEC↗ |
| SLRN ACELYRIN, Inc. | A Award deriv | 2023-05-04 | 2023-05-04 | 774,788 | — | $0 | 774,788 | SEC↗ |
| THRD Third Harmonic Bio, Inc. | A Award deriv | 2022-10-26 | 2022-10-27 | 13,667 | — | $0 | 13,667 | SEC↗ |
| SRZN Surrozen, Inc./DE | A Award deriv | 2022-06-07 | 2022-06-09 | 20,000 | — | $0 | 20,000 | SEC↗ |
| PRNB Principia Biopharma Inc. | D To issuer deriv | 2020-09-28 | 2020-09-28 | 20,475 | — | $0 | 0 | SEC↗ |
| PRNB Principia Biopharma Inc. | D To issuer deriv | 2020-09-28 | 2020-09-28 | 10,240 | — | $0 | 0 | SEC↗ |
| PRNB Principia Biopharma Inc. | D To issuer deriv | 2020-09-28 | 2020-09-28 | 10,240 | — | $0 | 0 | SEC↗ |
| PRNB Principia Biopharma Inc. | A Award deriv | 2020-06-04 | 2020-06-08 | 10,240 | — | $0 | 10,240 | SEC↗ |
| HZNP Horizon Therapeutics Publi | A Award deriv | 2020-01-21 | 2020-01-23 | 12,262 | — | $0 | 12,262 | SEC↗ |
| HZNP Horizon Therapeutics Publi | F Tax w/h | 2020-01-21 | 2020-01-23 | 2,716 | $38.25 | $103.9K | 109,668 | SEC↗ |
| HZNP Horizon Therapeutics Publi | A Award | 2020-01-21 | 2020-01-23 | 6,129 | — | $0 | 112,384 | SEC↗ |
| HZNP Horizon Therapeutics Publi | M Exercise deriv | 2020-01-05 | 2020-01-07 | 17,982 | — | $0 | 35,966 | SEC↗ |
| HZNP Horizon Therapeutics Publi | M Exercise deriv | 2020-01-05 | 2020-01-07 | 32,362 | — | $0 | 32,363 | SEC↗ |
| HZNP Horizon Therapeutics Publi | M Exercise | 2020-01-05 | 2020-01-07 | 50,344 | — | $0 | 108,703 | SEC↗ |
| HZNP Horizon Therapeutics Publi | A Award | 2020-01-05 | 2020-01-07 | 35,652 | — | $0 | 144,355 | SEC↗ |
| HZNP Horizon Therapeutics Publi | F Tax w/h | 2020-01-05 | 2020-01-07 | 38,100 | $36.10 | $1.38M | 106,255 | SEC↗ |
| HZNP Horizon Therapeutics Publi | M Exercise deriv | 2020-01-04 | 2020-01-07 | 17,892 | — | $0 | 35,784 | SEC↗ |
| HZNP Horizon Therapeutics Publi | F Tax w/h | 2020-01-04 | 2020-01-07 | 8,113 | $36.10 | $292.9K | 58,359 | SEC↗ |
| HZNP Horizon Therapeutics Publi | M Exercise | 2020-01-04 | 2020-01-07 | 17,892 | — | $0 | 66,472 | SEC↗ |
| HZNP Horizon Therapeutics Publi | A Award deriv | 2020-01-03 | 2020-01-07 | 36,284 | — | $0 | 36,284 | SEC↗ |
| PRNB Principia Biopharma Inc. | A Award deriv | 2019-06-11 | 2019-06-11 | 10,240 | — | $0 | 10,240 | SEC↗ |
| PRNB Principia Biopharma Inc. | A Award deriv | 2019-04-16 | 2019-04-18 | 20,475 | — | $0 | 20,475 | SEC↗ |
| HZNP Horizon Pharma plc | A Award | 2019-02-20 | 2019-02-22 | 35,652 | — | $0 | 63,326 | SEC↗ |
| HZNP Horizon Pharma plc | F Tax w/h | 2019-02-20 | 2019-02-22 | 15,795 | $21.54 | $340.2K | 47,531 | SEC↗ |
| HZNP Horizon Pharma plc | M Exercise deriv | 2019-01-05 | 2019-01-08 | 32,362 | — | $0 | 64,725 | SEC↗ |
| HZNP Horizon Pharma plc | M Exercise | 2019-01-05 | 2019-01-08 | 32,362 | — | $0 | 42,011 | SEC↗ |
| HZNP Horizon Pharma plc | F Tax w/h | 2019-01-05 | 2019-01-08 | 14,337 | $20.39 | $292.3K | 27,674 | SEC↗ |
| HZNP Horizon Pharma plc | M Exercise deriv | 2019-01-04 | 2019-01-08 | 17,891 | — | $0 | 53,676 | SEC↗ |
| HZNP Horizon Pharma plc | A Award deriv | 2019-01-04 | 2019-01-08 | 53,948 | — | $0 | 53,948 | SEC↗ |
| HZNP Horizon Pharma plc | F Tax w/h | 2019-01-04 | 2019-01-08 | 8,242 | $20.39 | $168.1K | 9,649 | SEC↗ |
| HZNP Horizon Pharma plc | M Exercise | 2019-01-04 | 2019-01-08 | 17,891 | — | $0 | 17,891 | SEC↗ |
| HZNP Horizon Pharma plc | A Award deriv | 2018-05-03 | 2018-05-07 | 97,087 | — | $0 | 97,087 | SEC↗ |
| HZNP Horizon Pharma plc | A Award deriv | 2018-01-04 | 2018-01-05 | 146,685 | — | $0 | 146,685 | SEC↗ |
| HZNP Horizon Pharma plc | A Award deriv | 2018-01-04 | 2018-01-05 | 71,567 | — | $0 | 71,567 | SEC↗ |